FOLD
Amicus Therapeutics Inc.
$9.03
+$0.13(+1.46%)
55
Overall
20
Value
91
Tech
--
Quality
Market Cap
$2.57B
Volume
4.89M
52W Range
$5.51 - $12.65
Target Price
$15.36
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $5.0M | $36.9M | $91.2M | $182.2M | $260.9M | $305.5M | $329.2M | $399.4M | $528.3M | ||
| Total Revenue | -- | $5.0M | $36.9M | $91.2M | $182.2M | $260.9M | $305.5M | $329.2M | $399.4M | $528.3M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | $-833.0K | $-6.2M | $-14.4M | $22.0M | $31.0M | $34.5M | $38.6M | $37.3M | $52.9M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $4.1M | $30.7M | $76.8M | $160.3M | $229.8M | $271.0M | $290.6M | $362.0M | $475.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-130.4M | $-186.0M | $-472.7M | $-405.6M | $464.3M | $476.8M | $477.5M | $495.1M | $439.2M | $450.5M | ||
| Research & Development | $76.9M | $104.8M | $149.3M | $270.9M | $286.4M | $308.4M | $272.0M | $276.7M | $152.4M | $109.4M | ||
| Research Expense | $76.9M | $104.8M | $149.3M | $270.9M | $286.4M | $308.4M | $272.0M | $276.7M | $152.4M | $109.4M | ||
| Selling, General & Administrative | $47.3M | $71.2M | $88.7M | $127.2M | $169.9M | $156.4M | $192.7M | $213.0M | $275.3M | $323.4M | ||
| Selling & Marketing Expenses | $47.3M | $71.2M | $88.7M | $127.2M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-2.6M | $-3.5M | $-3.9M | $-5.7M | $169.9M | $156.4M | $192.7M | $213.0M | $275.3M | $323.4M | ||
| Salaries & Wages | $-10.0M | $-17.5M | $-23.1M | $-29.3M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $1.8M | $3.2M | $3.6M | $4.2M | $4.8M | $8.8M | $6.2M | $5.3M | $7.9M | $8.5M | ||
| Depreciation & Amortization | $1.8M | $3.2M | $3.6M | $4.2M | $4.8M | $8.8M | $6.2M | $5.3M | $7.9M | $8.5M | ||
| Amortization | -- | $-248.0K | -- | -- | $197.8M | $197.8M | $199.3M | $1.5M | $199.4M | $199.6M | ||
| Other Operating Expenses | -- | -- | -- | -- | $10.8M | $11.1M | $10.0M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-126.0M | $-175.1M | $-247.8M | $-416.7M | $-304.0M | $-247.0M | $-206.4M | $-212.1M | $-77.2M | $24.9M | ||
| EBITDA | $-128.7M | $-195.3M | $-418.6M | $-311.5M | $-329.7M | $-243.0M | $-202.9M | $-196.9M | $-89.5M | $31.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.6M | $5.4M | $17.2M | $22.4M | $18.9M | $22.4M | $32.5M | $37.1M | $50.1M | $49.6M | ||
| Intinc | $929.0K | $1.6M | $4.1M | $10.5M | $10.2M | $3.2M | $509.0K | $3.0M | $7.1M | $5.4M | ||
| Net Non-Operating Interest Income/Expense | $-649.0K | $-3.8M | $-13.1M | $-11.9M | $-8.6M | $-19.2M | $-32.0M | $-34.1M | $-43.1M | $-44.2M | ||
| Gain on Sale of Securities | $50.0K | $32.0K | -- | $-2.7M | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $4.5M | $11.6M | $-277.3M | $-79.6M | $5.9M | $11.2M | $9.7M | $-3.5M | $32.4M | $9.4M | ||
| Other Special Charges | $-4.5M | $-11.6M | $277.3M | $82.3M | $-2.6M | $-8.1M | $-3.2M | $4.2M | $-29.8M | $-9.4M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $15.0K | $69.0K | -- | -- | -- | -- | -- | -- | -- | $9.2M | ||
| Special Income Charges | $-15.0K | $-69.0K | $-465.4M | -- | -- | -- | -- | $-6.6M | $-1.1M | $-9.2M | ||
| Impairment of Capital Assets | -- | -- | $465.4M | -- | -- | -- | -- | $6.6M | $1.1M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-130.5M | $-198.6M | $-431.9M | $-326.7M | $-337.0M | $-251.8M | $-178.6M | $-204.9M | $-100.0M | $20.8M | ||
| Pre-Tax Income | $-132.1M | $-203.8M | $-449.1M | $-349.1M | $-355.9M | $-274.3M | $-241.6M | $-242.0M | $-150.1M | $-28.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $952.0K | $9.6M | $-165.1M | $-94.0K | $478.0K | $2.6M | $8.9M | $-5.5M | $1.5M | $27.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $-132.1M | $-200.0M | $-284.0M | $-349.0M | $-356.4M | $-276.9M | $-250.5M | $-236.6M | $-151.6M | $-56.1M | ||
| Net Income (Continuing Operations) | $-132.1M | $-200.0M | $-284.0M | $-349.0M | $-356.4M | $-276.9M | $-250.5M | $-236.6M | $-151.6M | $-56.1M | ||
| Net Income (Discontinued Operations) | $-132.1M | $-200.0M | $-284.0M | $-349.0M | $-356.4M | $-276.9M | $-250.5M | $-236.6M | $-151.6M | $-56.1M | ||
| Net Income (Common Stockholders) | $-132.1M | $-200.0M | $-284.0M | $-349.0M | $-315.8M | $-276.9M | $-250.5M | $-236.6M | $-151.6M | $-56.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-130.4M | $-186.8M | $-478.9M | $-420.0M | $486.3M | $507.9M | $511.9M | $533.7M | $476.6M | $503.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $109.9M | $134.4M | $153.4M | $185.8M | $240.4M | $258.9M | $271.4M | $289.1M | $295.2M | $304.4M | ||
| Average Shares Outstanding (Diluted) | $110.1M | $134.3M | $153.5M | $185.6M | $240.4M | -- | $271.4M | $289.1M | $295.2M | $304.4M | ||
| Shares Outstanding | $125.2M | $194.8M | $186.9M | $223.7M | $257.2M | $264.3M | $308.2M | $282.7M | $295.4M | $300.1M | ||
| Basic EPS | -- | -- | -- | -- | $-1.48 | $-1.07 | $-0.92 | $-0.82 | $-0.51 | $-0.18 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.48 | $-1.07 | $-0.92 | $-0.82 | $-0.51 | $-0.18 | ||
| Diluted EPS | $-1.2 | $-1.49 | $-1.85 | $-1.88 | $-1.48 | $-1.07 | $-0.92 | $-0.82 | $-0.51 | $-0.18 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-0.92 | $-0.82 | $-0.51 | $-0.18 | ||
| OTHER METRICS | ||||||||||||
| Interest Expense Operating | -- | $-208.0K | -- | -- | -- | -- | $30.5M | -- | -- | -- | ||
| Other Gand A | $-2.6M | $-3.5M | $-3.9M | $-5.7M | $169.9M | $156.4M | $192.7M | $213.0M | $275.3M | $323.4M | ||
| Other Impairment Of Capital Assets | -- | -- | $-463.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-2.6M | $-3.5M | $-3.9M | $-5.7M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $47.3M | $71.2M | $88.7M | $127.2M | -- | -- | -- | -- | -- | -- | ||
| Restruct | $15.0K | $69.0K | -- | -- | -- | -- | -- | -- | -- | $9.2M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FOLD | $9.03 | +1.5% | 4.89M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amicus Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW